1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Chronic Myeloid Leukemia (CML) Treatment Market
2.2. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Treatment, 2023 (US$ Million)
2.3. Global Chronic Myeloid Leukemia (CML) Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Chronic Myeloid Leukemia (CML) Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Chronic Myeloid Leukemia (CML) Treatment Market Vendors
3.2. Strategies Adopted by Chronic Myeloid Leukemia (CML) Treatment Market Vendors
3.3. Key Industry Strategies
4. Chronic Myeloid Leukemia (CML) Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Chronic Myeloid Leukemia (CML) Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Targeted Therapy
5.3.1.1. Imatinib
5.3.1.2. Dasatinib
5.3.1.3. Nilotinib
5.3.1.4. Bosutinib
5.3.1.5. Ponatinib
5.3.2. Chemotherapy
5.3.3. Radiation Therapy
5.3.4. Splenectomy
5.3.5. Stem Cell Transplant 


6. North America Chronic Myeloid Leukemia (CML) Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
6.3.Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)

7. UK and European Union Chronic Myeloid Leukemia (CML) Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)

8. Asia Pacific Chronic Myeloid Leukemia (CML) Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)

9. Latin America Chronic Myeloid Leukemia (CML) Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
9.3.Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)

10. Middle East and Africa Chronic Myeloid Leukemia (CML) Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
10.3.Chronic Myeloid Leukemia (CML) Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Chronic Myeloid Leukemia (CML) Treatment Market: By Treatment, 2022-2032, USD (Million)

11. Company Profile
11.1. Novartis AG
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Bristol-Myers Squibb
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Teva Pharmaceuticals Industries Ltd.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. ARIAD Pharmaceuticals, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Pfizer, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Hospira, Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Prism Pharmaceuticals
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Incyte Corporation
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Bio-Path Holdings
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Stragen Pharma SA
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Otsuka Pharmaceutical Co., Ltd.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives